和络舒肝胶囊治疗血吸虫病肝硬化临床观察

目的观察和络舒肝胶囊治疗血吸虫病肝硬化的疗效。方法将确诊的96例血吸虫病肝硬化住院患者随机分为和络舒肝组、IFN-γ组和对照组,每组32例,分别采用和络舒肝胶囊、IFN-γ及常规治疗,疗程均为6个月,观察治疗前后患者临床症状、肝功能、血清透明质酸（HA）、Ⅲ型前胶原（PCIII）、层黏连蛋白（LN）、Ⅳ型胶原（L-IV）及肝脏B超影像学的变化。结果和络舒肝组患者治疗后肝功能指标、肝纤维化指标及B超影像学指标均较对照组有明显改善（P〈0.05）,与IFN-γ组患者比较差异无统计学意义（P〉0.05）。和络舒肝组患者治疗过程中未出现不良反应。结论和络舒肝胶囊能有效降低患者肝纤维化指标,改善肝功能,有明显抗肝纤维化疗效,且与IFN-γ的抗肝纤维化疗效相当,无明显不良反应,值得临床应用。

Therapeutic effects of capsule Huoluoshugan on schistosomal hepatocirrhosis

Objective To evaluate the therapeutic effects of capsule Huoluoshugan on sehistosomal hepatoeirrbosis. Methods Ninety-six patients with sehistosomal hepatoeirrhosis were selected and divided randomly into three groups： Huoluoshugan group, interferon-γ（IFN-γ） group and control group, and treated with capsule Huoluoshugan, IFN-γ and routine therapy, respectively. The course of treatment was 6 months in all groups. Before and after the treatment, the symptoms, physical signs, indexes of liver function and hepatic fibrosis, and changes of B-type ultrasonic images were detected for all the patients. Results The indexes of liver function, hepatic fibrosis and B-type ultrasonic image of the patients in Huoluoshugan group improved obviously compared with the control group after the treatment （P〈0. 05）, while the indexes above mentioned had no significant difference compared with the IFN-γ group （P〉0.05）. In addition, there was no obvious adverse reactions during the treatment in the patients of Huoluoshugan group. Conclusion Capsule Huoluoshugan can reduce the indexes of hepatic fibrosis and improve the liver function in patients with sehistosomal hepatoeirrbosis.